Bausch Health Companies - BHC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.88
  • Forecasted Upside: 8.50%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.02 (-0.24%)

This chart shows the closing price for BHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bausch Health Companies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHC

Analyst Price Target is $8.88
▲ +8.50% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Bausch Health Companies in the last 3 months. The average price target is $8.88, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 8.50% upside from the last price of $8.18.

This chart shows the closing price for BHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Bausch Health Companies. This rating has held steady since July 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2023Jefferies Financial GroupBoost Target$7.00 ➝ $9.50Low
9/9/2022Piper SandlerLower TargetNeutral$7.00 ➝ $6.00Low
9/1/2022Royal Bank of CanadaBoost TargetSector Perform$4.50 ➝ $8.00Low
8/10/2022Royal Bank of CanadaLower TargetSector Perform$5.00 ➝ $4.50Low
7/29/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$12.00 ➝ $5.00Low
7/28/2022Truist FinancialDowngradeBuy ➝ HoldLow
7/28/2022JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
6/13/2022JPMorgan Chase & Co.Initiated CoverageOverweight$12.00High
5/26/2022Piper SandlerLower Target$27.00 ➝ $7.00Low
5/15/2022Royal Bank of CanadaLower TargetOutperform$21.00 ➝ $17.00Low
5/11/2022BMO Capital MarketsLower Target$26.00 ➝ $15.00High
5/11/2022Bank of AmericaLower Target$25.00 ➝ $12.00High
5/9/2022Royal Bank of CanadaLower TargetOutperform$32.00 ➝ $21.00High
2/1/2022Royal Bank of CanadaLower TargetOutperform$40.00 ➝ $34.00Low
11/8/2021BMO Capital MarketsReiterated RatingHoldLow
11/3/2021Royal Bank of CanadaLower TargetOutperform$41.00 ➝ $40.00High
10/1/2021Jefferies Financial GroupReiterated RatingBuyHigh
8/4/2021BarclaysLower TargetIn-Line ➝ Overweight$35.00 ➝ $31.00High
7/8/2021HC WainwrightReiterated RatingBuyLow
5/5/2021Royal Bank of CanadaLower TargetOutperform$42.00 ➝ $41.00Low
3/30/2021Bank of AmericaReiterated RatingNeutral ➝ Underperform$27.00Low
3/24/2021Bank of AmericaDowngradeNeutral ➝ Underperform$27.00Low
3/16/2021HC WainwrightBoost TargetBuy$50.00 ➝ $55.00Low
3/14/2021JPMorgan Chase & Co.Reiterated RatingBuy$38.00Low
3/2/2021CitigroupBoost Target$32.00 ➝ $37.00Low
2/26/2021Morgan StanleyBoost TargetEqual Weight$22.00 ➝ $35.00Medium
2/25/2021BarclaysBoost TargetOverweight$27.00 ➝ $35.00Low
2/17/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$26.00 ➝ $42.00Low
2/16/2021JPMorgan Chase & Co.Boost TargetOverweight$32.00 ➝ $38.00Low
1/22/2021Piper SandlerDowngradeOverweight ➝ Neutral$25.00 ➝ $30.00Low
1/15/2021Jefferies Financial GroupBoost Target$27.00 ➝ $33.00Low
11/5/2020Piper SandlerLower TargetOverweight$26.00 ➝ $25.00Low
10/28/2020Wells Fargo & CompanyLower TargetEqual Weight$18.00 ➝ $17.00Medium
10/26/2020BarclaysBoost TargetOverweight$28.00 ➝ $29.00High
9/17/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$19.00High
8/24/2020HC WainwrightReiterated RatingBuy$64.00 ➝ $50.00High
8/19/2020Piper SandlerLower TargetOverweight$32.00 ➝ $26.00High
8/10/2020Royal Bank of CanadaBoost TargetSector Perform$23.00 ➝ $26.00Low
8/10/2020CitigroupLower TargetBuy$27.00 ➝ $26.00Medium
8/7/2020BarclaysBoost TargetOverweight$25.00 ➝ $28.00High
7/31/2020Royal Bank of CanadaLower TargetSector Perform$24.00 ➝ $23.00Low
7/7/2020Bank of AmericaBoost TargetUnderperform$12.00 ➝ $14.00High
6/17/2020HC WainwrightBoost TargetBuy$50.00 ➝ $64.00Medium
5/8/2020CfraLower TargetHold$28.00 ➝ $18.00Low
5/8/2020SunTrust BanksLower TargetBuy$25.00 ➝ $24.00High
5/8/2020Royal Bank of CanadaLower TargetSector Perform$25.00 ➝ $24.00High
4/30/2020Wells Fargo & CompanyBoost TargetEqual Weight$17.00 ➝ $18.00Low
4/28/2020HC WainwrightReiterated RatingBuy$50.00Medium
4/28/2020Royal Bank of CanadaLower TargetSector Perform$26.00 ➝ $25.00High
4/24/2020CitigroupInitiated CoverageBuy$30.00High
4/23/2020Jefferies Financial GroupLower TargetBuy$35.00 ➝ $27.00Medium
4/2/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
3/23/2020HC WainwrightLower TargetBuy$60.00 ➝ $50.00High
3/23/2020Wells Fargo & CompanyLower TargetEqual Weight$32.00 ➝ $17.00High
3/17/2020Royal Bank of CanadaLower TargetSector Perform$31.00 ➝ $26.00Medium
2/20/2020Royal Bank of CanadaLower TargetSector Perform$33.00 ➝ $31.00High
2/20/2020SunTrust BanksLower TargetBuy$32.00 ➝ $31.00Low
2/19/2020CowenReiterated RatingBuy$40.00Low
2/19/2020GuggenheimReiterated RatingBuy$36.00Low
2/11/2020Morgan StanleyLower TargetOverweight$34.00 ➝ $32.00Low
2/4/2020Royal Bank of CanadaBoost TargetSector Perform$31.00 ➝ $33.00High
1/29/2020Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
1/26/2020BarclaysReiterated RatingBuy$33.00Low
1/22/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$32.00Medium
12/30/2019Piper Jaffray CompaniesBoost TargetNeutral ➝ Overweight$30.00 ➝ $39.00Medium
12/23/2019HC WainwrightReiterated RatingBuy$60.00N/A
12/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$32.00 ➝ $38.00High
12/2/2019HC WainwrightReiterated RatingBuy$54.00 ➝ $60.00Low
12/2/2019The Goldman Sachs GroupInitiated CoverageNeutral$30.00Low
11/5/2019BarclaysBoost TargetOverweight$28.00 ➝ $30.00Low
10/25/2019CowenInitiated CoverageOutperform$35.00Medium
9/17/2019Wells Fargo & CompanyReiterated RatingSellLow
9/12/2019GuggenheimInitiated CoverageBuy$30.00High
8/15/2019TD SecuritiesUpgradeHold ➝ Buy$28.00Medium
8/7/2019HC WainwrightBoost TargetMarket Perform ➝ Buy$50.00 ➝ $54.00Low
7/29/2019HC WainwrightLower TargetBuy$58.00 ➝ $50.00Low
7/19/2019Wolfe ResearchInitiated CoverageOutperform ➝ Outperform$31.00Low
7/15/2019Wells Fargo & CompanyReiterated RatingSellLow
7/8/2019BarclaysSet TargetBuy$28.00Low
6/20/2019MizuhoSet TargetBuy$45.00Medium
6/11/2019Piper Jaffray CompaniesSet TargetBuy$29.00Medium
6/11/2019BarclaysReiterated RatingOverweight ➝ Overweight$28.00Medium
5/31/2019Cantor FitzgeraldSet TargetBuy$32.00Low
5/17/2019Wells Fargo & CompanySet TargetSell$9.00Low
5/13/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$24.80Low
5/7/2019MizuhoBoost TargetBuy$41.00 ➝ $45.00Low
4/25/2019Cantor FitzgeraldReiterated RatingBuy$32.00Low
4/2/2019Piper Jaffray CompaniesSet TargetBuy$28.00Low
3/20/2019Bank of AmericaReiterated RatingUnderperform$18.00High
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$30.00High
3/18/2019MizuhoBoost TargetBuy$39.00 ➝ $41.00High
2/28/2019HC WainwrightReiterated RatingBuyMedium
2/19/2019Wells Fargo & CompanyBoost TargetSell ➝ Underperform$9.00 ➝ $25.19High
1/6/2019MizuhoReiterated RatingBuy$39.00High
1/2/2019UBS GroupUpgradeBuyHigh
1/1/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$27.00High
12/17/2018Morgan StanleySet TargetBuy$32.00High
12/14/2018HC WainwrightUpgradeAverage ➝ BuyLow
12/12/2018Wells Fargo & CompanySet TargetSell$9.00Medium
11/30/2018MizuhoBoost TargetBuy ➝ Buy$35.00 ➝ $38.00Low
11/13/2018BMO Capital MarketsReiterated RatingHold$26.00Medium
11/7/2018TD SecuritiesBoost TargetHold$24.00 ➝ $28.00Low
11/7/2018Royal Bank of CanadaBoost TargetHold$30.00 ➝ $31.00Medium
11/6/2018Cantor FitzgeraldReiterated RatingBuyN/A
11/5/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$32.00High
10/15/2018HC WainwrightSet TargetHold$25.00Low
10/8/2018HC WainwrightSet TargetHold$25.00Medium
10/8/2018MizuhoReiterated RatingBuy$35.00Medium
10/8/2018Royal Bank of CanadaSet TargetSector Perform ➝ Hold$26.00 ➝ $30.00Medium
9/13/2018HC WainwrightReiterated RatingHold$25.00High
9/13/2018Piper Jaffray CompaniesUpgradeUnderweight ➝ Neutral$16.00 ➝ $19.00High
9/12/2018Deutsche Bank AktiengesellschaftSet TargetBuy$30.00High
9/12/2018Cantor FitzgeraldReiterated RatingBuy$32.00High
8/31/2018HC WainwrightReiterated RatingHold$20.00Medium
8/13/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$20.00 ➝ $22.00Medium
8/8/2018Royal Bank of CanadaBoost TargetHold$25.00 ➝ $26.00Low
8/8/2018JPMorgan Chase & Co.Boost TargetUnderweight$18.00Low
8/7/2018Piper Jaffray CompaniesSet TargetSell$16.00Low
8/7/2018Cantor FitzgeraldReiterated RatingBuy$32.00Low
8/7/2018MizuhoReiterated RatingBuy$31.00High
8/6/2018Wells Fargo & CompanyReiterated RatingSellHigh
7/23/2018Piper Jaffray CompaniesSet TargetSell$13.00Low
6/29/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
6/29/2018MizuhoReiterated RatingBuy$31.00Medium
6/22/2018TD SecuritiesDowngradeBuy ➝ Hold$24.00Low
6/20/2018HC WainwrightReiterated RatingHold$20.00Low
6/6/2018BarclaysUpgradeEqual Weight ➝ Overweight$20.00 ➝ $34.00High
6/5/2018HC WainwrightSet TargetHold$20.00High
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 9 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 9 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Bausch Health Companies logo
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
Read More

Today's Range

Now: $8.18
Low: $8.09
High: $8.38

50 Day Range

MA: $7.38
Low: $5.72
High: $8.80

52 Week Range

Now: $8.18
Low: $4.00
High: $10.23


831,376 shs

Average Volume

4,554,822 shs

Market Capitalization

$2.96 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch Health Companies?

The following Wall Street analysts have issued research reports on Bausch Health Companies in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada,, and Truist Financial Co..
View the latest analyst ratings for BHC.

What is the current price target for Bausch Health Companies?

4 Wall Street analysts have set twelve-month price targets for Bausch Health Companies in the last year. Their average twelve-month price target is $8.88, suggesting a possible upside of 8.5%. JPMorgan Chase & Co. has the highest price target set, predicting BHC will reach $12.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $6.00 for Bausch Health Companies in the next year.
View the latest price targets for BHC.

What is the current consensus analyst rating for Bausch Health Companies?

Bausch Health Companies currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BHC, but not buy more shares or sell existing shares.
View the latest ratings for BHC.

What other companies compete with Bausch Health Companies?

How do I contact Bausch Health Companies' investor relations team?

Bausch Health Companies' physical mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company's listed phone number is (514) 744-6792 and its investor relations email address is [email protected]. The official website for Bausch Health Companies is Learn More about contacing Bausch Health Companies investor relations.